A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastric Adenocarcinoma

Interventions

DRUG: Rivoceranib
DRUG: Placebo

Sponsor

Elevar Therapeutics